XLV250110C90000
- 0.00
- 0.000.00%
The Health Care Select Sector SPDR® Fund Newsroom
Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Merck Rival Summit Draws New Buy From Truist on Deal Prospects
Pfizer Analyst Ratings
Sector Update: Health Care Stocks Rise Premarket Wednesday
Pfizer And GSK's RSV Vaccines Safety Labels Updated, FDA Adds Warning For Rare Neurological Disorder
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of FOMC Meeting Minutes
Merck Gets Expanded Approval From China for Its HPV Vaccine in Males
Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday
This Adobe Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
AbbVie Analyst Ratings
Merck & Co Analyst Ratings
Merck's male HPV vaccine has been approved domestically for the first time. Industry insiders believe this will promote the future approval of domestic products under development.
① Gardasil has become the first and currently the only approved HPV vaccine for men in China. ② Industry experts believe that the approval of the new indication is a new exploration in terms of pharmacological principles and other aspects. ③ Currently, companies such as Kang Li Wei Shi and Beijing Wantai Biological Pharmacy Enterprise have made arrangements in this field.
Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
Arbutus Could Benefit From Big Pharma Bird Flu Vaccines: Jefferies
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
Psychiatric Hospital Operator Acadia Healthcare Earns Upgrade Amid Expected Recovery In 2025
These Stocks Are Expected to See at Least 25% Revenue Growth in 2025 – Wolfe
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Unpacking the Latest Options Trading Trends in Merck & Co